Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- Neurodevelopmental Outcomes in Craniosynostosis Repair: Complete Statistical AnalysisIndependent statistical analysis of Neurodevelopmental Outcomes in Craniosynostosis Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04072783).
- Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders: Complete Statistical AnalysisIndependent statistical analysis of Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03398070).
- Neuropathic Pain Syndrome Patient Study (MK-0000-072): Complete Statistical AnalysisIndependent statistical analysis of Neuropathic Pain Syndrome Patient Study (MK-0000-072): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00570310).
- Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- New Onset Type 1 Diabetes: Role of Exenatide: Complete Statistical AnalysisIndependent statistical analysis of New Onset Type 1 Diabetes: Role of Exenatide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01269034).
- New Treatment for Alcohol and Nicotine Dependence: Complete Statistical AnalysisIndependent statistical analysis of New Treatment for Alcohol and Nicotine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182766).
- NewHopeIndependent statistical analysis of Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NEwTON AFIndependent statistical analysis of Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NEXSCOTIndependent statistical analysis of Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Next Generation X-ray Imaging System: Complete Statistical AnalysisIndependent statistical analysis of Next Generation X-ray Imaging System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04571099).
- NEXT2Independent statistical analysis of Efficacy of Esomeprazole in Patients With Frequent Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01370538).
- NF107-BMP2Independent statistical analysis of A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NFPIndependent statistical analysis of Nurse-Family Partnership Impact Evaluation in South Carolina: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03360539).
- NGAM-05Independent statistical analysis of High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01313507).
- NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: primary endpoint results, effect estimate…
- NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03929913).
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03369340).
- NIHO12Independent statistical analysis of Accuracy of Pulse Oximeters With Profound Hypoxia During Motion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04814342).
- NIKAIA 1Independent statistical analysis of To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus: primary endpoint results, effect estimate…
- NILOdeepRIndependent statistical analysis of Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).
- NIRAFIndependent statistical analysis of Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- Nitrite Infusion in Islet Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Nitrite Infusion in Islet Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544242).
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…
- NKTR-214Independent statistical analysis of A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval,…
- NMES Efficacy on Patients With NBPP: Complete Statistical AnalysisIndependent statistical analysis of NMES Efficacy on Patients With NBPP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01999465).
- NMES for Achilles Tendon Rupture: Complete Statistical AnalysisIndependent statistical analysis of NMES for Achilles Tendon Rupture: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04727047).
- NO-ASPIRATEIndependent statistical analysis of Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02284178).
- no-cryIndependent statistical analysis of Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NOCTIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults: primary endpoint…
- NOHARMIndependent statistical analysis of Novel Use Of Hydroxyurea in an African Region With Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01976416).
- NOLANIndependent statistical analysis of NOLAN: Naproxen or Loratadine and Neulasta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712009).
- NOM-ERAIndependent statistical analysis of Non-Operative Management and Early Response Assessment in Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03904043).
- Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events: Complete Statistical AnalysisIndependent statistical analysis of Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03183063).